Pressmeddelanden, rapporter och bolagsmeddelande för Dancann Pharma

Summary: The financial results for DanCann Pharma A/S for the fourth quarter of 2024 show an increase in net sales and significant improvements in EBITDA compared to the previous year. Net sales for Q4-2024 were 1,350 DKK, while the full year 2024 saw net sales of 7,764 DKK, up from 6,074 DKK in 2023. EBITDA improved by 63.8% year-over-year, moving from -12.88 million DKK in 2023 to -4.66 million DKK in 2024. The equity ratio increased to 0.90 from 0.53. CEO Jeppe Krog Rasmussen noted that the year was pivotal, with both opportunities and challenges, including increased competition and regulatory complexities. The report includes insights into strategic progress, financial potential from asset sales, cost reductions, market competition impacts, revised future guidance, and product approval status. DanCann Pharma A/S is a Danish biopharmaceutical company focused on cannabinoids, listed on the Spotlight Stock Market. The report also contains forward-looking statements with associated risks and uncertainties.